Skip to main content

Table 3 FEV 1 change from baseline at week 12 (day 84) by country, ITT population

From: Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

 

VI 25 mcg OD (n = 101)

SAL 50 mcg BD (n = 100)

Placebo (n = 95)

Germany (N = 28)

62 (127.6)

175 (156.2)

19 (221.6)

Peru (N = 104)

391 (433.8)

360 (364.7)

492 (591.9)

Poland (N = 59)

279 (310.4)

251 (513.9)

117 (615.6)

Ukraine (N = 43)

158 (238.7)

127 (198.5)

200 (253.9)

United States (N = 62)

519 (568.2)

392 (756.0)

400 (522.5)

  1. Values are weighted mean (SD) 0–24 hour weighted mean serial FEV1 (ml).
  2. BD: twice-daily; FEV1: forced expiratory volume in one second; ITT: intent-to-treat; n: number of patients used in analysis; OD: once-daily; SAL: salmeterol; SD: standard deviation; VI: vilanterol.
Back to article page

Journal of Negative Results in BioMedicine

ISSN: 1477-5751

Contact us